Todos Medical And Nlc Pharma Announce Primary And Secondary Endpoints Met In Nlc-V-01 Phase 2 Clinical Trial Of Oral Antiviral 3Cl Protease Inhibitor Tollovir
By, Admin1 min read
Share
Phase 2 Study Nlc-V-01 Closed Early After Interim Data Analysis Due To Positive Clinical Efficacy
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
